Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

393 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The risk of weekend biopsy: Impact of specimen source and fixation status on HER2 assessment in the treatment of advanced gastric cancer (The HER_WEEKEND study).
Nakamura M, Watanabe A, Yoshizawa A, Iwasaki S, Nomura A, Matsumura M, Murai T, Itaya K, Koike Y, Izumi T, Endo A, Kato S, Ono Y, Ohshima T, Okazaki N, Nakagawa S, Ishii Y, Fukasawa Y, Yokota I, Tsuji T, Nishikawa S. Nakamura M, et al. Among authors: yokota i. Pathol Int. 2023 Oct;73(10):509-519. doi: 10.1111/pin.13367. Epub 2023 Aug 17. Pathol Int. 2023. PMID: 37589434 Free PMC article.
Durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small-cell lung cancer (NEJ056).
Furuta M, Horinouchi H, Yokota I, Yamaguchi T, Itoh S, Fukui T, Iwashima A, Sugisaka J, Miura Y, Tanaka H, Miyawaki T, Yokouchi H, Miura K, Saito R, Saito G, Kamoshida T, Uchinami Y, Kato T, Kobayashi K, Asahina H. Furuta M, et al. Among authors: yokota i. Cancer Sci. 2024 Nov;115(11):3705-3717. doi: 10.1111/cas.16340. Epub 2024 Sep 15. Cancer Sci. 2024. PMID: 39278260 Free PMC article.
Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory B-cell lymphoma: the first real-world evidence in Japan.
Goto H, Kitawaki T, Fujii N, Kato K, Onishi Y, Fukuhara N, Yamauchi T, Toratani K, Kobayashi H, Yoshida S, Shimo M, Onodera K, Senjo H, Onozawa M, Hirata K, Yokota I, Teshima T. Goto H, et al. Among authors: yokota i. Int J Clin Oncol. 2023 Jun;28(6):816-826. doi: 10.1007/s10147-023-02334-w. Epub 2023 Apr 18. Int J Clin Oncol. 2023. PMID: 37071252
Additional statin treatment enhances the efficacy of HER2 blockade and improves prognosis in Rac1-high/HER2-positive breast cancer.
Kato C, Iizuka-Ohashi M, Honda M, Konishi E, Yokota I, Boku S, Mizuta N, Morita M, Sakaguchi K, Taguchi T, Watanabe M, Naoi Y. Kato C, et al. Among authors: yokota i. Biochim Biophys Acta Mol Basis Dis. 2024 Dec;1870(8):167458. doi: 10.1016/j.bbadis.2024.167458. Epub 2024 Aug 10. Biochim Biophys Acta Mol Basis Dis. 2024. PMID: 39128642 Free article.
Results of the JRS-I LRA0401 and LRB0402 Japan Rhabdomyosarcoma Study Group trials for low-risk embryonal rhabdomyosarcoma.
Hosoi H, Miyachi M, Teramukai S, Sakabayashi S, Tsuchiya K, Kuwahara Y, Onodera R, Matsuyama K, Yokota I, Hojo H, Okita H, Hata JI, Hamasaki M, Tsuneyoshi M, Oda Y, Nakazawa A, Kato M, Takimoto T, Horibe K, Hara JI, Suita S, Hanada R, Masaki H, Nozaki M, Ikeda H, Kishimoto S, Kaneko M, Kawai A, Morikawa Y. Hosoi H, et al. Among authors: yokota i. Int J Clin Oncol. 2024 Nov;29(11):1746-1755. doi: 10.1007/s10147-024-02608-x. Epub 2024 Aug 23. Int J Clin Oncol. 2024. PMID: 39177879
393 results